1.
Zentralbl Gynakol
; 110(5): 277-82, 1988.
Article
in German
| MEDLINE
| ID: mdl-3376611
ABSTRACT
Cisplatinum (DDP) is a cell cycle-independent drug used to prolong the survival time in ovarian cancer patients operated palliatively. After six therapeutic cycles of 100 mg of cisplatinum (Platidiam, Lachema, Brno) per square meter of body surface each changes in the sensation of hearing like tinnitus without any limitation of the faculty of hearing felt individually have been reported in four out of twelve ovary cancer patients. A high frequency loss of more than 4,000 Hz could be detected by threshold audiometry in three out of these twelve patients.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/adverse effects , Cisplatin/adverse effects , Hearing Loss, Sensorineural/chemically induced , Ovarian Neoplasms/drug therapy , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Audiometry, Pure-Tone , Cisplatin/administration & dosage , Female , Hearing Loss, High-Frequency/chemically induced , Humans , Middle Aged , Tinnitus/chemically induced
2.
Psychiatr Neurol Med Psychol (Leipz)
; 34(11): 678-9, 1982 Nov.
Article
in German
| MEDLINE
| ID: mdl-7170325
3.
Vestn Otorinolaringol
; (3): 34-6, 1982.
Article
in Russian
| MEDLINE
| ID: mdl-7101612
4.
Z Arztl Fortbild (Jena)
; 68(4): 175-8, 1974 Feb 15.
Article
in German
| MEDLINE
| ID: mdl-4838429